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Abstract
Introduction: Glycyrrhizin (GL) was recently found to suppress high-mobility group box 1 (HMGB1)-induced injury
by binding directly to it. However, the effect of GL on HMGB1 expression in endotoxemia as well as its underlying
molecular mechanism remained unclear.
Methods: Twenty-one pigs were divided into four groups: sham group (n = 3), control group (n = 6), ethyl
pyruvate group (n = 6) and glycyrrhizin group (n = 6). Pigs were anesthetized, mechanically ventilated, monitored
and given a continuous intravenous infusion of lipopolysaccharide (LPS). Twelve hours after the start of the LPS
infusion, ethyl pyruvate (30 mg/kg/hr) or glycyrrhizin (1 mg/kg/hr) was administered for 12 hours. Systemic and
pulmonary hemodynamics, oxygen exchange, and metabolic status were measured. The concentrations of
cytokines in serum and the corresponding gene and protein expressions in tissue samples from liver, lungs,
kidneys, small intestine and lymph nodes were measured.
Results: GL maintained the stability of systemic hemodynamics and improved pulmonary oxygen exchange and
metabolic status. GL also attenuated organ injury and decreased the serum levels of HMGB1 and other pro-
inflammatory cytokines by inhibiting their gene and protein expression.
Conclusions: GL improved systemic hemodynamics and protected vital organs against porcine endotoxemia
through modulation of the systemic inflammatory response. By reducing the serum level and gene expression of
HMGB1 and other pro-inflammatory cytokines, GL may become a potential agent for the treatment of sepsis.
Introduction
Sepsis is a systemic host response to infection with a
clinical spectrum ranging from hemodynamic changes
to multiple organ dysfunction syndrome and even death,
and it is the leading cause of death in surgical intensive
care unit patients [1,2]. A harmful host response to bac-
terial infection is believed to be the key origin of sepsis,
in which invading bacteria and their products such as
lipopolysaccharide (LPS) are potent activators of the
inflammatory reaction [3]. The pathogenesis of sepsis
involves a complex process of cellular activation at multi-
ple levels resulting in release of pro-inflammatory cyto-
kines such as TNF-a, IL-1b, high-mobility group box 1
(HMGB1) and anti-inflammatory cytokines, such as IL-10.
Other mechanisms include activation of neutrophils,
monocytes and microvascular endothelial cells as well as
activation of the complement, coagulation and fibrinolytic
systems [4,5]. Sepsis is characterized by impaired regula-
tion of these inflammatory responses but the exact mole-
cular mechanism is still poorly understood.
In early studies, the efficacy of anti-TNF-a and IL-1
receptor-antagonist therapies in human sepsis were disap-
pointing, partly because TNF-a and IL-1b were released
early in the development of sepsis, thereby limiting the
effect of such therapies. Unlike other pro-inflammatory
cytokines, HMGB1 is a late appearing inflammatory cyto-
kine and might become a unique target for treatment in
sepsis, since it provides a sufficient time frame for clinical
intervention against progressive inflammatory disorders [6].
HMGB1, originally described as a ubiquitous nuclear
protein, has also been shown to be a late inflammatory
cytokine in sepsis. HMGB1 may be ‘passively released’
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from damaged or necrotic cells in injured tissues or
‘actively secreted’ by immune cells, including macrophages
and monocytes in response to infection, peaking at
approximately 20 hours after stimulation [7,8]. Moreover,
HMGB1 may trigger an inflammatory response and con-
tribute to the pathological progression of infectious and
inflammatory disorders, such as enhancing the production
of TNF-a, IL-1b and nitric oxide [9,10].
Several strategies of HMGB1-based therapy have been
studied. Neutralizing strategies for HMGB1 inhibition
including ‘A-box’ or anti-HMGB1 antibody treatment,
have successfully reduced mortality in mice with polymi-
crobial sepsis. This effect was presumably due to blockade
of HMGB1 binding to cell surface receptors, thereby
attenuating its pro-inflammatory capability [11]. In a dif-
ferent strategy, pharmacological agents were studied for
HMGB1-inhibiting effects. Ethyl pyruvate (EP), a stable
aliphatic ester used as a nontoxic food additive as well as
an experimental anti-inflammatory agent, was found to
specifically inhibit LPS-induced HMGB1 secretion, to
decrease circulating HMGB1 levels and to inhibit p38
mitogen-activated protein kinase (MAPK) and nuclear fac-
tor-kappa B (NF-B) activation, ultimately resulting in
improved survival in a murine sepsis model [12,13]. In a
phase II multicenter double-blind placebo-controlled
study of EP in high-risk patients undergoing cardiac sur-
gery with cardiopulmonary bypass (CPB), neither benefit
nor side-effect was found with EP administration [14]. No
clinical study of EP in sepsis patients was found and the
safety and efficacy of EP need more investigation.
Herbal remedies, such as Danggui (Angelica sinensis)
[15], Green tea (Camellia sinensis) [16,17], and Danshen
(Saliva miltorrhiza) [18] have also been found to reduce
mortality in septic animals by inhibiting HMGB1 secre-
tion. Glycyrrhizinic acid or glycyrrhizin (GL) [19], a glyco-
conjugated triterpene extracted from the root of
Leguminosae Glycyrrhiza glabra L. was recently found to
decrease the concentration of HMGB1 by binding directly
to it and, therefore, to suppress HMGB1-induced injury
[20,21]. This could be partly explained by the anti-inflam-
matory properties of GL and might direct the future
design of new derivatives with improved HMGB1-binding
properties [22]. GL has many pharmacologic actions,
including anti-inflammatory, anti-viral, anti-tumor and
hepatoprotective activities [23-25] and has been used clini-
cally for more than 20 years for allergic diseases and
chronic hepatitis in China and Japan. Although its safety
and efficacy are widely accepted, the effect of GL on
HMGB1 expression in sepsis or endotoxemia as well as
the underlying molecular mechanism has not been
reported up to now.
In the present study, GL was administered in a porcine
endotoxemic model to examine its effects on systemic
hemodynamics and organ functions as well as systemic
and local inflammatory reactions while EP was used as a
positive control. We further hypothesized that GL could
protect against porcine endotoxemia through modulation
of the systemic inflammatory response by reducing the




The study protocol was approved by the Animal Care and
Use Committee of Fudan University (Shanghai, China).
Twenty-one minipigs with a median body weight of 20 kg
(range, 18 to 25 kg) were fasted for 24 hours with free
access to water. All experiments were performed in the
Covidien Clinical Institute, Shanghai, China.
Anesthesia
After premedication with ketamine 15 mg/kg and midazo-
lam 0.5 mg/kg intramuscularly, an ear vein was cannulated
and midazolam 0.5 mg/kg and atropine 0.02 mg/kg were
given intravenously before endotracheal intubation.
Anesthesia was maintained with a continuous infusion of
propofol 5 to 8 mg/kg/hr and fentanyl (30 μg/kg/hr during
the surgical preparation and reduced to 5 μg/kg/hr for the
rest of the experiment) and midazolam 0.5 mg/kg/hr. No
muscle relaxants were used. Mechanical ventilation was
initiated in constant-flow, volume-cycled mode (840 venti-
lator, Puritan Bennett, Tyco Healthcare, Carlsbad, CA,
USA), with a tidal volume (VT) of 10 to 12 ml/kg, a fre-
quency of 15 breaths/minute, a positive end expiratory
pressure (PEEP) of 5 cmH2O, an inspiratory to expiratory
time ratio of 1:2, and an inspired oxygen fraction of 0.50.
Ringer’s solution was infused at 7 to 20 mL/kg/hr during
surgery to maintain normovolemia.
Catheterization and measurement
A thermodilution Swan-Ganz catheter(5F, Arrow Interna-
tional Inc., Reading, PA, USA) was advanced into the pul-
monary artery to be used for measuring mean pulmonary
artery pressure (MPAP), pulmonary artery wedge pressure
(PAWP) and central venous pressure (CVP). A femoral
artery catheter (18G, Braun, Melsungen, Germany) was
inserted to monitor heart rate (HR) and mean arterial
pressure (MAP) and to sample blood. A central venous
catheter (14F, Arrow International) was inserted via the
left femoral vein to infuse fluid and drugs. Cystostomy was
performed and a catheter was placed to measure urine
output.
Arterial blood gas analyses (i-STAT, Abbott Point of
Care Inc., Princeton, NJ, USA), including pH, PaCO2,
PaO2, HCO3, lactate, base excess (BE), and SaO2, were
performed at data collection points. A portion of the
blood sample was examined for the following hematolo-
gical parameters: white blood cell (WBC), red blood cell
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(RBC), hemoglobin (Hb) and platelet (Plt) counts, pro-
thrombin time (PT), alanine aminotransferase (Alt),
creatinine (Cr) andserum sodium.
Experimental protocol
The animals were randomly assigned to four groups:
sham group (n = 3, 3 males, body weight 21.67 ± 2.08
kg), control (con) group (n = 6, 3 males/3 females, body
weight 18.67 ± 1.15 kg), EP treatment (EP) group (n =
6, 4 males/2 females, body weight 20.00 ± 1.73 kg), GL
treatment (GL) group (n = 6, 3 males/3 females, body
weight 21.67 ± 2.89 kg).
All animals were allowed to stabilize for at least
60 minutes after surgery. After baseline data collection,
the animals in the sham group were only anesthetized
and infused with Ringer’s solution, and the animals in
the other three groups were given intravenous LPS
(Escherichia coli 0111:B4, Sigma Chemical, St. Louis,
Mo, USA, 20 mg/L in 5% dextrose) infusion and Ringer’s
solution for 24 hours. LPS was started at 1.7 μg/kg/hr
until MPAP reached 35 mmHg in 2 hours; then the infu-
sion rate was adjusted to maintain MPAP at 35 to
45 mmHg for the remaining 22 hours. If MAP decreased
below 50 mmHg despite additional intravenous fluids,
the LPS infusion was temporarily suspended. After
12 hours of continuous intravenous LPS infusion, the EP
group received EP (Sigma Chemical) 30 mg/kg as loading
dose over 10 minutes followed by 30 mg/kg/hr for
12 hours; the GL group received GL (Minophagen Phar-
maceutical Co., Tokyo, Japan) 1 mg/kg as loading dose
over 10 minutes followed by 1 mg/kg/hr for 12 hours
(Figure 1). The additional intravenous fluid for the four
groups was as follows: sham 6.95 ± 0.79, con 9.86 ± 1.28,
EP 9.62 ± 0.55, and GL 9.07 ± 0.71 ml/kg/hr. Hydro-
xyethylstarch (HAES-Steril® 6% 200/0.5, Fresenius Kabi,
Erlangen, Germany) was administered as required to
maintain MAP > 60 mmHg, and 5% glucose solution was
infused to keep arterial blood glucose levels between 5 to
7 mmol/L [1,26]. Con, EP and GL groups received similar
amount of HAES (con, 64.0 ± 8.19, EP, 67.33 ± 6.66, and
GL, 63.33 ± 4.93 ml).
Systemic and pulmonary hemodynamics, oxygen
exchange, and metabolic parameters were measured
6 hours, 12 hours (that is, immediately before EP or
GL), 18 hours and 24 hours after the start of LPS infu-
sion. Blood samples were collected at 6, 12, 18 and
24 hours after the start of LPS infusion. During the
experiment, body temperature was maintained between
37.5 and 38.5°C using external cooling and heating pads.
After completion of the experiment, the animals were
sacrificed by potassium chloride injection under deep
anesthesia.
Tissue specimens from lung, liver, kidney, small intes-
tine and lymph node were aseptically harvested and put
into 10% formalin for pathological examination (H & E
stain) or snap frozen in liquid nitrogen (-180°C) and
then stored at -80°C for western-blot and real-time PCR.
Histopathology
After H & E stain, at least six random areas (× 200)
from each section were analyzed using a scoring system
[see Additional file 1] [27]. The lung was assessed for
leukocyte infiltration, hemorrhage and alveolar wall
thickness. Liver samples were assessed for interstitial
edema and leukocyte infiltration. The kidney was
assessed for interstitial edema, leukocyte infiltration and
Figure 1 Experimental design. After stabilization, LPS was infused to pigs for 24 hours and after 12 hours, the EP and GL groups were treated
with the corresponding drug. Systemic and pulmonary hemodynamics, gas exchange and metabolic status were measured and blood samples
collected at 6, 12, 18 and 24 hours. EP, ethyl pyruvate; GL, glycyrrhizin; LPS, lipopolysaccharide.
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capillary congestion. The small intestine was assessed
for Gruenhagen’s spaces, denuded surface and intersti-
tial edema.
Cytokine measurements
Concentrations of HMGB1, IL-1b, TNF-a, IL-6 and IL-10
in serum samples were determined simultaneously by
using a commercial ELISA kit (HMGB1, IBL International
GmbH, Hamburg, Germany; TNF-a, R&D Systems, Min-
neapolis, MN, USA; IL-6, antibodies-online Inc., Atlanta,
GA, USA; and IL-1b, IL-10, ALPCO Diagnostics, Salem,
NH, USA). Samples and standards were prepared follow-
ing the manufacturer’s instructions and analyzed on a
microplate reader (Model 680, Bio-Rad Laboratories, Inc.,
Hercules, CA, USA). The detection limits were 0.5 ng/ml
for HMGB1, 10 pg/ml for IL-1b, 10 pg/ml for TNF-a,
50 pg/ml for IL-6 and 10 pg/ml for IL-10. The intra-assay
variations were 2.8% to 3.4% for HMGB1, 3.4% to 6.8% for
IL-1b, 4.3% to 6.9% for TNF-a, 3.5% to 5.9% for IL-6 and
3.2% to 6.0% for IL-10. The inter-assay variations were
3.8% to 6.4%, 8.4% to 9.8%, 7.3% to 9.9%, 6.5% to 11.9%
and 5.3% to 8.0% for the same cytokines, respectively.
Diamine oxidase and D-lactate Assay
Concentrations of diamine oxidase (DAO) and D-lactate
in serum samples were determined by using a DAO
ELISA kit (E0656p, EIAab Science Co., Wuhan, China) or
D-lactate Colorimetric Assay Kit (K667-100, BioVision,
Inc., Milpitas, CA, USA). Samples and standards were pre-
pared following the manufacturer’s instructions and ana-
lyzed on a microplate reader (Model 680, Bio-Rad
Laboratories, Inc.). The detection limits were 0.5 U/ml for
DAO and 0.01 nmol/μl for D-lactate. The intra-assay var-
iations were 3.0% to 6.2% for DAO and 3.2% to 6.0% for
D-lactate. The inter-assay variations were 8.8% to 11.9%
and 6.6% to 10.0% for DAO and D-lactate, respectively.
Western-blot
Frozen tissue samples were pulverized and homogenized
in a homogenization buffer (10 mmol/L phosphate buffer,
250 mmol/L sucrose, 1 mmol/L ethylenediaminetetraace-
tic acid (EDTA), 0.1 mmol/L phenylmethanesulfonyl fluor-
ide (PMSF) and 0.1% tergitol, pH 7.5). Homogenates were
centrifuged at 27 000g for 10 minutes at 4°C and superna-
tant as total protein extracts were isolated. Nuclear protein
was extracted following the manufacturer’s instructions
using a nuclear extract kit (40010 & 40410, Active Motif,
Carlsbad, CA, USA) to determine NF-B p65. Protein
extracts were resolved on 12% SDS polyacrylamide gel and
transferred to nitrocellulose membranes. The membranes
were probed overnight at 4°C with the following primary
antibodies: antibody against HMGB1 (LS-B2841) (LifeSpan
Biosciences, Inc., Seattle, WA, USA), IL-10 (sc-74141),
VCAM-1(vascular cell adhesion molecule 1, sc-73252)
(Santa Cruz Biotechnology, Inc., Santa Cruz, CA., USA),
antibody against IL-6 (ab11746), antibody against b-actin
(ab3280) (Abcam plc., Cambridge, MA, USA), antibody
against NF-B p65 (ABIN121274) (antibodies-online Inc.),
antibody against ICAM-1(intercellular adhesion molecule-
1, Boster Biological Technology, Ltd., Wuhan, China) and
the secondary antibody (sc-358914, sc-2004, sc-2006)
(Santa Cruz Biotechnology, Inc.), respectively.
Antibodies were diluted to a final concentration of 0.5
to 2 μg/ml. The protein bands were visualized by a che-
miluminescence imaging system (ChemiDoc™ XRS,
Bio-Rad Laboratories, Inc.). The signal intensity was
quantified by ImageJ 1.44 software. Densitometric analy-
sis of the expression levels of specific proteins on the
immunoblots was normalized to that of b-actin. Repre-
sentative immunoblots from five independent experi-
ments are shown.
Real-time PCR
Total RNA was extracted by using the RNeasy Mini Kit
(Qiagen, Hilden, Germany). Contaminating DNA was
removed using RNase-Free DNase Set (Qiagen). cDNA
was generated from 1 μg total RNA, and 1/20th of the
cDNA mixture was used for quantitative reverse tran-
scription in the 7300 Real-time PCR System (ABI, Carls-
bad, CA, USA). Approximately 25 μl of reaction mixture
was used for the real-time PCR assay that consisted of 2
× (12.5 μl) SYBR green supermix (TIANGEN BIOTECH
CO., Beijing, China), 1 μl primers (0.5 μl each from the
stock), 11 μl of water, and 0.5 μl of template. The ther-
mal conditions consisted of an initial denaturation at
95°C for 10 minutes followed by 40 cycles (30 seconds
at 95°C, 30 seconds at 58°C, 30 seconds at 72°C). The
sequences of primers used are listed in Additional file 2,
Table S1. All reactions were carried out in triplicate to
reduce variation.
The data were analyzed using ABI Prism 7300 SDS
software. Data normalization was accomplished using
the endogenous control (b-actin) and the normalized
values were subjected to a 2-ΔΔCt formula to calculate
the fold change between the control and experiment
groups.
Statistical analysis
All data are expressed as mean ± SD. Comparison
between groups was performed by repeated measure-
ments analysis of variance (ANOVA) for the data as
continuous variables (that is, systemic and pulmonary
hemodynamics, oxygen exchange and metabolic data),
followed by post hoc testing with Fisher’s protected
least significant difference test. For other data, differ-
ences within each group were tested using a two way
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ANOVA and a subsequent Student-Newman-Keuls for
multiple comparisons. In all cases, P < .05 was regarded
as statistically significant.
Results
Systemic and pulmonary hemodynamics, oxygen
exchange and metabolic data
Con, EP and GL groups received similar LPS infusions (con,
1.23 ± 0.27; EP, 1.37 ± 0.21; GL, 1.30 ± 0.24 μg/kg/hr).
Systemic and pulmonary hemodynamics, oxygen exchange
and metabolic data are summarized in Table 1.
There were no differences between groups in baseline
hemodynamics (HR, MAP, MPAP, CVP and PAWP),
which remained unaltered throughout the experiment in
the sham group (P > .05). LPS infusion increased MPAP
(P < .05), whereas MAP decreased compared to the
sham group (P < .05). Both CVP and PAWP remained
stable throughout the experiment without intergroup
difference.
There were no differences between groups in arterial
pH, PaCO2 and HCO3, whereas PaO2 significantly
decreased as a result of LPS infusion. EP and GL increased
PaO2, which meant the oxygen exchange was improved in
the EP and GL groups.
Effect of GL on organ injury in endotoxemic pigs
As shown in Table 2 GL and EP markedly reversed the
increase of WBC and decrease of Plt induced by LPS.
Cr in the GL or EP group was significantly lower than
in the con group, although Cr in all groups increased
compared with baseline.
Microscopy of lung tissue showed that LPS caused a
marked infiltration of inflammatory cells and hemorrhage
in the con group compared to the sham group, whereas
such changes were obviously attenuated in the GL group
(Figure 2, Table 3). In the liver, EP and GL led to signifi-
cant decreases in interstitial WBCs. The sections of the
kidney showed a significant decrease in interstitial edema,
leukocyte infiltration and capillary congestion when EP
and GL were used. EP and GL also caused a significant
decrease of Gruenhagen’s spaces, denuded surface and
interstitial edema in the small intestine (Figure 2, Table 3).
There was no obvious injury in the lymph nodes in each
group.
The RNA transcripts of ICAM-1, VCAM-1 and PBEF
(pre-B-cell colony-enhancing factor) in the lung were sig-
nificantly up-regulated by LPS compared to the sham
group, whereas treatment with GL or EP reduced the
extent of such up-regulation (Figure 3A). The protein of
ICAM-1 and VCAM-1 in the lung showed changes similar
to mRNA in the four groups (Figure 3B, C). As indicators
of small intestine injury, DAO and D-lactate in serum
increased due to LPS, and GL attenuated such responses
with DAO and D-lactate while EP affected D-lactate only
(Figure 4).
Effect of GL on serum HMGB1, IL-1b, TNF-a and IL-10
levels
Serum cytokine concentrations in the four groups are
shown in Figure 5. HMGB1 levels in serum were signifi-
cantly elevated in the con, GL and EP groups compared
with the sham group but were reduced after GL or EP
administration.
Endotoxemia induced a characteristic cytokine
response with high levels of key inflammatory cytokines,
such as IL-1b, TNF-a and IL-6, but EP and GL signifi-
cantly attenuated such responses compared with the con
group. An increase in IL-10 induced by LPS was also
detected but the peak of IL-10 appeared later than that
of the other inflammatory cytokines. The IL-10 level
was not affected by EP significantly. The IL-4 level
began to decline after 12 hours of LPS infusion, and GL
or EP further enhanced the trend.
Effect of GL on HMGB1, IL-1b, TNF-a cytokines and NF-B
gene and protein expression
As shown in Figures 6 and 7, expression levels of HMGB1
mRNA and protein in lungs, liver, kidneys, small intestine
and lymph node were enhanced markedly after endotoxe-
mia compared with the sham group. Treatment with GL
or EP reduced expression levels of HMGB1 mRNA and
protein in the five organs, especially in the lung and small
intestine compared with the con group. Endotoxemia also
up-regulated the expression of NF-B p65 mRNA and
increased activated protein of NF-B p65 in the five
organs compared with the sham group. The levels of NF-
B p65 mRNA and activated protein in most of the organs
were markedly lower in the GL or EP group than the con
group.
Compared with the con group, GL markedly down-
regulated the expression of IL-6 mRNA in the lung and
liver, but did not significantly alter the expression IL-10
mRNA (Figure 6). In the lung, kidney and intestine, EP
or GL significantly reduced the level of IL-6 protein, but
again, GL did not reduce the level of IL-10 protein in
any of the five organs (Figure 7).
Discussion
In the present study, a porcine model of endotoxemia
was chosen because the effect of continuous low-dose
LPS simulated the systemic response of endotoxemia,
therefore a better observation of systemic and pulmon-
ary hemodynamic changes and vital organ function
could be made. As a positive control, EP maintained the
stability of systemic hemodynamics and protected vital
organ functions. More importantly, EP protected against
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Table 1 Systemic and pulmonary hemodynamics, oxygen exchange and metabolic data.
Baseline 6 hours 12 hours 18 hours 24 hours
pH
Sham 7.47 ± 0.01 7.47 ± 0.01 7.47 ± 0.01 7.46 ± 0.04 7.46 ± 0.02
Con 7.47 ± 0.01 7.42 ± 0.02 7.41 ± 0.03 7.41 ± 0.03 7.44 ± 0.03
EP 7.48 ± 0.03 7.46 ± 0.03 7.39 ± 0.03 7.38 ± 0.02 7.40 ± 0.04
GLab 7.57 ± 0.02 7.41 ± 0.09 7.51 ± 0.14 7.40 ± 0.05 7.38 ± 0.07
PaCO2 (mmHg)
Sham 38.8 ± 1.9 38.3 ± 3.2 39.3 ± 2.8 40.2 ± 2.8 39.0 ± 3.2
Con 40.9 ± 1.8 43.9 ± 2.7 42.6 ± 2.3 42.9 ± 2.6 41.9 ± 2.6
EP 37.2 ± 3.0 37.9 ± 4.8 36.5 ± 1.8 36.4 ± 2.5 36.3 ± 2.0
GL 36.1 ± 2.0 36.5 ± 11.9 35.6 ± 10.7 43.2 ± 5.4 40.8 ± 5.9
PaO2 (mmHg)
Sham 251.7 ± 16.3 234.7 ± 19.4 231.3 ± 32.3 240.3 ± 17.6 230.0 ± 19.5
Cona 255.3 ± 13.9 168.3 ± 16.9 170.0 ± 19.5 181.0 ± 14.6 189.3 ± 23.3
EPab 254.3 ± 12.2 164.3 ± 17.4 175.7 ± 14.2 223.7 ± 20.0 221.0 ± 34.1
GLab 257.7 ± 13.4 161.3 ± 22.3 172.7 ± 13.9 231.3 ± 22.2 229.0 ± 24.8
HCO3 (mmHg)
Sham 29.5 ± 2.7 28.3 ± 1.8 29.1 ± 2.2 30.2 ± 3.0 29.0 ± 2.5
Con 32.1 ± 3.1 30.6 ± 1.7 30.1 ± 1.3 29.0 ± 1.5 30.2 ± 1.8
EPab 29.8 ± 3.4 27.0 ± 1.4 23.8 ± 1.1 23.4 ± 1.4 23.9 ± 1.6
GL 33.3 ± 2.1 33.0 ± 6.7 29.3 ± 5.6 30.3 ± 5.1 33.5 ± 4.5
BE (mmol/L)
Sham 3.7 ± 1.5 2.7 ± 1.2 3.3 ± 2.1 1.7 ± 0.6 1.7 ± 1.5
Cona 4.0 ± 3.1 0.3 ± 2.7 -2.7 ± 2.1 -2.0 ± 1.5 -3.3 ± 2.3
EPab 4.3 ± 1 1.0 ± 0.9 -2.7 ± 1.0 -1.0 ± 0.9 1.0 ± 0.6
GLab 4.0 ± 1.3 0.3 ± 0.8 -1.7 ± 1.4 -0.3 ± 1.4 1.5 ± 0.5
Lactate (mmol/L)
Sham 0.8 ± 0.4 0.9 ± 0.4 1.0 ± 0.5 0.9 ± 0.4 1.0 ± 0.5
Cona 0.9 ± 0.4 1.9 ± 0.6 2.6 ± 0.8 2.4 ± 0.1 2.3 ± 0.2
EPab 1.3 ± 0.4 2.1 ± 0.6 2.7 ± 0.8 1.3 ± 0.4 1.1 ± 0.3
GLab 1.2 ± 0.6 2.5 ± 1.0 3.3 ± 1.4 1.4 ± 0.9 1.0 ± 0.5
HR (beats/min)
Sham 126.7 ± 7.0 123.0 ± 16.6 121.0 ± 11.5 123.0 ± 7.9 129.3 ± 4.0
Cona 135.0 ± 13.4 89.3 ± 8.5 90.0 ± 7.2 97.7 ± 7.2 102.3 ± 8.7
EPa 125.0 ± 11.8 88.3 ± 14.9 88.0 ± 6.3 100.3 ± 4.9 109.0 ± 4.5
GLa 123.0 ± 10.1 87.7 ± 8.3 92.7 ± 9.6 102.3 ± 7.2 114.7 ± 9.0
MAP (mmHg)
Sham 94.3 ± 8.02 95.3 ± 4.7 87.7 ± 8.5 85.7 ± 6.0 82.7 ± 6.8
Cona 89.3 ± 7.2 67.7 ± 12 64.3 ± 7.6 65.7 ± 9.6 67.0 ± 12.6
EPab 82.7 ± 8.3 65.7 ± 11.5 63.7 ± 7.4 72.7 ± 9.6 84.3 ± 9.3
GLab 84.3 ± 11.5 63.7 ± 5.1 60.0 ± 5.6 76.3 ± 5.8 85.7 ± 4.6
MPAP (mmHg)
Sham 20.7 ± 4.7 22.7 ± 7.2 26.3 ± 6.8 25.3 ± 5.0 26.3 ± 6.4
Con 19.3 ± 1.4 39.3 ± 7.6 37.3 ± 4.4 38.7 ± 2.7 38.0 ± 2.4
EP 19.7 ± 4.6 37.7 ± 3.6 37.7 ± 2.7 33.0 ± 2.4 30.7 ± 2.1
GL 20.3 ± 4.6 37.0 ± 3.2 38.7 ± 2.6 36.7 ± 1.0 31.3 ± 4.4
CVP (mmHg)
Sham 11.0 ± 2.0 10.3 ± 0.6 12.3 ± 3.8 15.3 ± 2.5 12.3 ± 2.3
Con 11.7 ± 2.1 11.3 ± 0.5 13.3 ± 2.6 11.7 ± 3.7 10.3 ± 1.9
EP 9.0 ± 2.4 9.3 ± 4.2 11.3 ± 4.5 11.0 ± 5.0 12.3 ± 3.4
GL 13.3 ± 2.3 14.0 ± 4.7 12.7 ± 4.6 13.0 ± 3.9 13.7 ± 2.9
PAWP (mmHg)
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porcine endotoxemia through modulation of systemic
and local inflammatory responses.
The main findings of this study were that, following LPS
treatment: 1) GL could better maintain the stability of
systemic hemodynamics and improve pulmonary oxygen
exchange and metabolic status. 2) GL might protect organ
function by regulating excessive inflammatory reactions. 3)
GL inhibited the gene and protein expression of HMGB1
Table 1 Systemic and pulmonary hemodynamics, oxygen exchange and metabolic data. (Continued)
Sham 8.0 ± 1.7 7.3 ± 1.5 6.7 ± 1.2 7.3 ± 0.6 7.3 ± 1.5
Con 7.0 ± 1.8 7.3 ± 2.6 8.3 ± 3.4 8.0 ± 3.2 7.0 ± 0.9
EP 8.7 ± 3.1 8.0 ± 2.4 7.0 ± 0.9 9.3 ± 1.4 7.3 ± 1.4
GL 7.7 ± 1.4 6.7 ± 1.9 6.0 ± 0.9 6.3 ± 1.9 7.7 ± 1.4
Urine (ml/kg/h)
Sham 0 5.0 ± 0.5 6.4 ± 1.1 6.1 ± 1.0 5.1 ± 1.0
Con 0 6.4 ± 1 6.0 ± 1.8 6.0 ± 1.5 5.5 ± 0.8
EPab 0 6.1 ± 0.9 7.5 ± 1.1 7.7 ± 1.0 8.5 ± 1.1
GLab 0 5.1 ± 0.8 6.7 ± 0.8 7.4 ± 1.0 8.0 ± 0.6
aP < 0.05 versus sham group by repeated measures ANOVA; bP < 0.05 versus Con group by repeated measures ANOVA. Data are mean ± SD. ANOVA, analysis of
variance; BE, base excess; Con, control; CVP, central venous pressure; EP, ethyl pyruvate; GL, glycyrrhizin; HR, heart rate; MAP, mean arterial pressure; MPAP, mean
pulmonary artery pressure; PAWP, pulmonary artery wedge pressure.
Table 2 Blood cell count, chemistry and organ functions.
Baseline 6 hours 12 hours 18 hours 24 hours
WBC (×109/L)
Sham 11.8 ± 2.1 11.6 ± 1.4 13.1 ± 1.4 15.0 ± 2.4 15.1 ± 1.5
Cona 9.3 ± 0.4 3.2 ± 0.5 3.8 ± 0.5 17.2 ± 0.3 22.0 ± 3.9
EPab 9.7 ± 1.9 3.3 ± 0.9 3.2 ± 0.6 11.3 ± 1.8 13.3 ± 2.7
GLab 9.5 ± 3.7 3.4 ± 1.3 4.3 ± 0.8 9.0 ± 1.8 13.5 ± 5.9
Plt (×1012/L)
Sham 278.7 ± 10.4 291.7 ± 14.6 292.7 ± 11.0 276.3 ± 11.1 273.7 ± 17.6
Cona 274.7 ± 39.8 158.7 ± 21.3 64.0 ± 3.1 57.3 ± 9.0 53.7 ± 9.1
EPab 316.7 ± 48.8 139.0 ± 14.2 68.0 ± 9.1 169.3 ± 40.4 185.0 ± 7.6
GLab 343.3 ± 45.2 165.0 ± 20.1 85.0 ± 18.5 184.3 ± 15.8 172.0 ± 16.3
Alt (mmol/L)
Sham 52.7 ± 6.4 55.3 ± 4.5 55.3 ± 8.4 55.7 ± 3.2 57.7 ± 5.0
Cona 59.3 ± 4.8 71.0 ± 8.3 69.0 ± 7.0 75.7 ± 12.5 75.0 ± 8.9
EPa 56.3 ± 5.9 68.0 ± 5.7 72.0 ± 8.0 73.3 ± 8.1 74.3 ± 7.6
GLab 59.0 ± 5.5 71.3 ± 5.4 72.8 ± 5.6 57.7 ± 4.1 56.0 ± 6.4
Cr (mmol/L)
Sham 71.3 ± 8.4 77.0 ± 9.6 79.7 ± 9.0 83.0 ± 6.6 88.3 ± 5.8
Cona 70.0 ± 3.9 83.7 ± 6.9 119.7 ± 6.7 181.3 ± 14.5 211.0 ± 21.7
EPab 77.7 ± 6.6 81.0 ± 4.6 109.3 ± 5.1 146.0 ± 33.1 180.7 ± 11.9
GLab 74.7 ± 12.1 82.0 ± 23.3 111.7 ± 27.9 116.7 ± 21.2 143.7 ± 15.9
PT (seconds)
Sham 11.2 ± 1.2 12.0 ± 1.9 12.0 ± 1.6 11.9 ± 1.9 12.4 ± 2.4
Cona 11.2 ± 1.6 12.1 ± 1.6 14.8 ± 2.3 14.9 ± 1.7 14.4 ± 2.2
EPa 10.4 ± 0.5 12.1 ± 1.3 14.3 ± 1.9 15.4 ± 1.3 15.1 ± 1.5
GLa 10.9 ± 0.8 12.6 ± 1.3 14.4 ± 0.7 14.8 ± 1.2 14.9 ± 1.3
Na (mmol/L)
Sham 140.7 ± 1.2 141.3 ± 1.5 143.7 ± 2.3 144.0 ± 1.0 144.7 ± 1.2
Cona 140.7 ± 3.6 141.7 ± 1.4 140.7 ± 2.3 139.3 ± 2.9 140.7 ± 2.3
EP 144.0 ± 0.9 143.0 ± 0.9 144.0 ± 0.9 139.3 ± 5.7 143.0 ± 2.7
GLb 145.3 ± 2.3 145.7 ± 2.9 143.0 ± 0.9 143.3 ± 3.6 143.7 ± 3.6
aP < 0.05 versus sham group by repeated measures ANOVA; bP < 0.05 versus Con group by repeated measures ANOVA; Data are mean ± SD. Alt, alanine
aminotransferase; ANOVA, analysis of variance; Con, control; Cr, creatinine; EP, ethyl pyruvate; GL, glycyrrhizin; Plt, platelet; PT, prothrombin time; WBC, white
blood cell.
Wang et al. Critical Care 2013, 17:R44
http://ccforum.com/content/17/2/R44
Page 7 of 13
and other pro-inflammatory cytokines and decreased their
concentrations which might result from the inhibition of
NF-B p65.
GL stabilized the systemic hemodynamics and improved
pulmonary oxygen exchange which achieved the effect
similar to that of EP. We also found an obvious decrease
in PaO2 after infusion of LPS but a distinct increase in
PaO2 after the administration of GL, suggesting improved
pulmonary oxygenation and systemic acidosis as reflected
by the change of blood lactate and BE. Pathological exami-
nation revealed improvement in alveolar hemorrhage,
infiltration of inflammatory cells and interstitial pulmon-
ary edema, which was in line with other experimental
findings.
Our data indicated that GL protected the lung func-
tion, not only improving the oxygenation of the lungs,
but also decreasing the expression of ICAM-1, VCAM-1
and PBEF in the lungs significantly. DAO and D-lactate
have been used as novel markers of intestinal ischemia
and bacterial infection in the intestine [28,29]. In the
present study, a significant increase in DAO and D-lac-
tate serum levels in the con group indicated marked
intestinal injury, while GL decreased the levels of DAO
and D-lactate and attenuated intestinal injury. Although
pseudo-aldosteronism, with sodium retention, hypoka-
laemia and hypertension, is a well-known side-effect of
GL [30], no obvious electrolyte disturbance due to GL
was found in our experiment. Overall, our study indi-
cated that GL improved cardiovascular, respiratory and
other vital organ functions during endotoxemia which
resulted in protection against damage to multiple
organs.
Regulation of the excessive inflammatory reactions
might be a major mechanism by which GL exerted its
protective effect. In the porcine model, we observed that
serum and protein levels of both HMGB1 and other pro-
inflammatory cytokines in the liver, lungs, kidneys, small
intestine and lymph nodes increased significantly after
Figure 2 Organ injury in each group [hematoxylin and eosin (H&E), yellow bar = 100 μm, white bar = 50 μm]. Lung: A marked
infiltration of inflammatory cells and hemorrhage were seen in the control group. The EP and GL groups had slighter leukocyte infiltration and
almost no hemorrhage. Liver: The control group was marked by interstitial edema. The EP group had a similar change but to a lesser extent.
Kidney: The control group had significant interstitial edema and capillary congestion. The EP and GL groups had slighter edema and almost no
capillary congestion. Intestine: Severe edema was observed in the small intestine of the control group. The EP and GL groups had similar change
but to a lesser extent. EP, ethyl pyruvate; GL, glycyrrhizin.
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LPS infusion, while treatment with GL reduced their
serum levels in those organs. A significant reduction of
HMGB1 protein in these organs except lymph nodes was
observed (Figure 7), but interestingly, the mRNA level of
HMGB1 was down-regulated only in the lungs and small
intestine (Figure 6). It might be related to the HMGB1-
binding characteristics of GL [21], which might acceler-
ate the degradation of HMGB1 protein.
Several mechanisms have been proposed for the actions
of GL: (1) it inhibited glucocorticoid metabolism and
potentiated their effects [31,32]; (2) it exerted its effects
through the influence of cytokines and chemokines
(TNF-a, IL-1b, IFN-g, IL-10, Eotaxin-1, etc.), ICAM-1, P-
selectin and some enzymes like inducible nitric oxide
synthase [33-35]; (3) it suppressed LPS-induced activa-
tion of signaling cascades and the expression of
Table 3 Histological score.
Histological change Sham Con EP GL
Lung
Leukocyte infiltration 0.92 ± 0.32 2.85 ± 0.61a 1.92 ± 0.36a 1.7 ± 0.36ab
Hemorrhage 0.7 ± 0.13 3.14 ± 0.57a 1.52 ± 0.12ab 1.65 ± 0.56ab
Alveolar wall thickness 0.92 ± 0.32 1.78 ± 0.26a 1.74 ± 0.68 1.36 ± 0.47
Liver
Interstitial edema 0.77 ± 0.33 1.86 ± 0.32a 1.37 ± 0.16ab 1.65 ± 0.3a
Leukocyte infiltration 0.33 ± 0.27 2.64 ± 0.48a 1.67 ± 0.46ab 1.36 ± 0.32ab
Kidney
Interstitial edema 1.3 ± 0.19 2.32 ± 0.35a 1.65 ± 0.14ab 1.64 ± 0.19ab
Leukocyte infiltration 0.64 ± 0.15 3.01 ± 0.34a 2.67 ± 0.32ab 2.11 ± 0.19ab
Capillary congestion 0.24 ± 0.17 3.12 ± 0.13a 1.96 ± 0.22ab 1.69 ± 0.18ab
Small intestine
Gruenhagen’s spaces 0.67 ± 0.13 2.36 ± 0.34a 1.65 ± 0.35ab 1.32 ± 0.28ab
Denuded Surface 0.89 ± 0.32 2.17 ± 0.12a 1.35 ± 0.32b 1.41 ± 0.16ab
Interstitial edema 0.4 ± 0.24 3.15 ± 0.37a 1.98 ± 0.27ab 1.31 ± 0.17ab
aP < 0.05 versus sham group, bP < 0.05 versus Con group. Con, control; EP, ethyl pyruvate; GL, glycyrrhizin.
Figure 3 mRNA expression of ICAM-1, VCAM-1 and PBEF and protein expression of ICAM-1 and VCAM-1 in lung. A) Real-time PCR
showed that the expression levels of ICAM-1, VCAM-1 and PBEF mRNA decreased significantly in the EP and GL groups compared to the control
group. B) Western-blot showed that the expression levels of ICAM-1 and VCAM-1 protein decreased significantly in the EP and GL groups
compared to the control group. C) Quantitative assessment of protein relative to b-actin showed that the expression levels of ICAM-1 and
VCAM-1 protein decreased significantly in the EP and GL groups compared to the control group. * P < 0.05 versus the control group. EP, ethyl
pyruvate; GL, glycyrrhizin; ICAM-1, intercellular adhesion molecule-1; PBEF, pre-B-cell colony-enhancing factor; VCAM-1, vascular cell adhesion
molecule 1.
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pro-inflammatory genes through the inhibition of NF-B
and PI3K activity [36,37].
IL-10 has various functions and is considered the most
important anti-inflammatory cytokine in maintaining
immune system balance. IL-10 could inhibit the activation
of macrophages, monocytes and T cells, and limit the
secretion of pro-inflammatory cytokines, such as TNF-a,
IL-1, IL-6, and IL-12 [38]. Our data indicated that IL-10
serum levels and gene expression showed no significant
difference between the GL group and the con group. IL-10
may inhibit the excessive inflammatory reaction more effi-
ciently, because IL-10 levels did not decrease while TNF-a
and HMGB1 levels decreased at the same time. The exact
mechanism needs further investigation.
NF-B plays a key role in the initiation and progression
of inflammatory reactions. The transcription factor NF-
B has been shown to be a major regulator of many func-
tionally diverse pro-inflammatory cytokines [39]. Active
NF-B promotes the gene expression of pro-inflamma-
tory cytokines, such as TNF-a, IL-1b and HMGB1, adhe-
sion molecules and chemokines [40]. Menegazzi [34]
demonstrated that GL decreased the levels and gene
expression of TNF-a and IL-1b in the pleural exudates
and lung tissues, and the inhibition effect might be
Figure 4 Concentration of diamine oxidase and D-lactate in plasma. Diamine oxidase and D-lactate in plasma increased in the control
group and decreased after EP or GL was used. *P < 0.05 versus sham group by repeated measures ANOVA; # P < 0.05 versus con group by
repeated measures ANOVA. ANOVA, analysis of variance; con, control; EP, ethyl pyruvate; GL, glycyrrhizin.
Figure 5 Concentration of plasma cytokine. *P < 0.05 versus
sham group by repeated measures ANOVA; # P < 0.05 versus con
group by repeated measures ANOVA. ANOVA, analysis of variance;
con, control.
Figure 6 mRNA expression of HMGB1, NF-B p65, IL-6 and IL-
10. Realtime PCR showed the expression levels of HMGB1, NF-B
p65 (NF-B), IL-6 and IL-10 mRNA in lung, liver, kidney, intestine and
lymph node. * P < 0.05 versus control group. HMBG1, high-mobility
group box 1; NK-B, nuclear factor-kappaB.
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Figure 7 Protein expression of HMGB1, NF-B p65, IL-6 and IL-10. A) Western-blot showed the expression levels of HMGB1, NF-B p65 (NF-
B), IL-6 and IL-10 in lung, liver, kidney, intestine and lymph node. The expression of NF-B p65 was detected using nuclear protein while others
were detected using total protein. B) Quantitative assessment of protein relative to b-actin. * P < 0.05 versus control group. HMBG1, high-
mobility group box 1; NK-B, nuclear factor-kappaB.
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associated with the prevention of NF-B and STAT-3
activation. We found that GL inhibited NF- B gene
expression (liver, lungs and kidneys) and NF- B activa-
tion (liver, lungs, kidneys, small intestine and lymph
nodes). At the same time, it decreased the serum levels of
TNF-a, IL-1b and HMGB1, and exerted a protective
effect against the damage related to pro-inflammatory
cytokines. These results imply that GL inhibits the gene
expression of such cytokines by inhibiting NF-B expres-
sion and activation, but the exact molecular mechanism
is unknown. Receptor for advanced glycation end pro-
ducts (RAGE), a major membrane receptor for HMGB1,
has been shown to mediate activation of NF-B [41] and
positively regulate NF-B p65 expression [42]. This sug-
gests that HMGB1 and NF-B may form a positive feed-
back loop and GL may modulate the excessive
inflammatory and immune responses through its
HMGB1-binding capability. However, the underlying
molecular mechanism and interaction still awaits further
exploration.
In this porcine model of endotoxemia, GL improved sys-
temic hemodynamics, enhanced pulmonary oxygen
exchange and protected against damage to multiple organs.
These effects could be attributed to its regulation of exces-
sive inflammatory and immune responses by reducing
serum levels and gene expression of HMGB1 and other
pro-inflammatory cytokines. Therefore, GL could protect
against porcine endotoxemia through modulation of sys-
temic inflammatory response, and GL might become a
potential agent for the treatment of sepsis in the future.
Further basic and clinical investigations are warranted in
this area.
Conclusions
GL could improve systemic hemodynamics and protect
vital organs against porcine endotoxemia through mod-
ulation of the systemic inflammatory response, and GL
might become a potential agent for the treatment of
sepsis.
Key messages
• GL could maintain the stability of systemic hemo-
dynamics, improve pulmonary oxygen exchange and
metabolic status in porcine endotoxemia.
• GL attenuated organ injury induced by LPS.
• GL decreased the serum levels of HMGB1 and
other pro-inflammatory cytokines through inhibiting
their gene and protein expression.
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